Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 1313–1315.

https://doi.org/10.1182/blood-2022-166225

Published: 2022

Journal Articles

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Blood (2022) 140 (Supplement 1): 10976–10978.

https://doi.org/10.1182/blood-2022-162944

Published: 2022

Journal Articles

The Dramatic Impact of the War on Access to Treatment for Lymphoma Patients. a Report from the Ukrainian Lymphoma Registry

Yana Stepanishyna, Iryna Kriachok, Nazar Shokun, Nataliia Shapovalenko, Anisiia Luchkiv, Tetiana Skrypets, Martina Manni, Massimo Federico

Blood (2022) 140 (Supplement 1): 9525.

https://doi.org/10.1182/blood-2022-166484

Published: 2022

Journal Articles

A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

Herve Ghesquieres, Youenn Drouet, Susan L. Slager, Franck Morschhauser, Sara Galimberti, Dennis P. Robinson, Emilie Thomas, Anne J. Novak, Luc Xerri, Stefano Luminari, Aurelie Verney, Camille Laurent, Lisa M. Rimsza, Thomas M. Habermann, Massimo Federico, Brian K. Link, Gilles Salles, James R. Cerhan

Blood (2022) 140 (Supplement 1): 1307–1309.

https://doi.org/10.1182/blood-2022-167466

Published: 2022

Journal Articles

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Blood (2022) 140 (Supplement 1): 1476–1478.

https://doi.org/10.1182/blood-2022-158883

Published: 2022

Journal Articles

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Stefano Luminari, Alexander Fosså, Judith Trotman, Daniel Molin, Francesco Annibale d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A. Kirkwood, Peter Johnson

Blood (2022) 140 (Supplement 1): 766–767.

https://doi.org/10.1182/blood-2022-162780

Published: 2022

Journal Articles

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 811.

https://doi.org/10.1182/blood-2021-148581

Published: 2021

Journal Articles

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2021) 138 (Supplement 1): 41.

https://doi.org/10.1182/blood-2021-146773

Published: 2021

Journal Articles

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, Massimo Federico

Blood (2021) 138 (3): 213–220.

https://doi.org/10.1182/blood.2020010387

Published: 2021

Includes: Supplemental data

Journal Articles

Adult T-Cell Leukemia/Lymphoma: A Cohort of 41 Cases Recorded in the Brazilian T-Cell Project

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142818

Published: 2020

Journal Articles

Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Angie Mae Rodday, PhD, Susan K Parsons, MD MRP, Carlton Scharman, MD, Ranjana Advani, MD, Massimo Federico, MD, Jonathan W. Friedberg, MD MSSc, Andrea Gallamini, MD, David C. Hodgson, MD MPH, FRCPC, Peter Hoskin, MD, Martin Hutchings, MD PhD, Peter Johnson, MD FRCP, Kara M. Kelly, MD, Brian K. Link, MD, John A. Radford, MD FMedSci, Pier Luigi Zinzani, MD, James R. Cerhan, MD PhD, John Raemaekers, MD, Andrew M. Evens, DO,MMSc, On Behalf Of The HoLISTIC Consortium

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-135935

Published: 2020

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Sara Alonso, MD, Martina Manni, PhD, Clementine Sarkozy, MD, Marielle Wondergem, MD, Attilio Guarini, MD, Laura Magnano, MD, Miguel Alcoceba, PhD, Martine E.D. Chamuleau, MD, Sara Galimberti, Maria Gomes da Silva, MD, Harald Holte, MD PhD, Emanuele Zucca, MD, Silvia Montoto, MD, Sandra Lockmer, MD, Igor Aurer, MD PhD, Luigi Marcheselli, MSc, Dolores Caballero, MD, Gilles Salles, MD PhD, Massimo Federico, MD

Blood (2018) 132 (Supplement 1): 4145.

https://doi.org/10.1182/blood-2018-99-115956

Published: 2018

Journal Articles

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Robert Stuver, MD, Niloufer Khan, MD, Marc Schwartz, Mark Acosta, Massimo Federico, MD, Christian Gisselbrecht, Frederick Lansigan, MD, Lauren C. Pinter-Brown, MD, Barbara Pro, MD, Andrei R. Shustov, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Salvia Jain, MD

Blood (2018) 132 (Supplement 1): 2926.

https://doi.org/10.1182/blood-2018-99-112869

Published: 2018

Journal Articles

Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study

Anne Ségolène Cottereau, Annibale Versari, Stefano Luminari, Jehan Dupuis, Loïc Chartier, René-Olivier Casasnovas, Alina Berriolo-Riedinger, Massimo Menga, Corinne Haioun, Hervé Tilly, Vittoria Tarantino, Massimo Federico, Gilles Salles, Judith Trotman, Michel Meignan

Blood (2018) 131 (22): 2449–2453.

https://doi.org/10.1182/blood-2017-11-816298

Published: 2018

Includes: Supplemental data

Journal Articles

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Blood (2018) 131 (13): 1456–1463.

https://doi.org/10.1182/blood-2017-07-795476

Published: 2018

Includes: Supplemental data

Journal Articles

Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project

Blood (2017) 130 (Supplement 1): 1512.

https://doi.org/10.1182/blood.V130.Suppl_1.1512.1512

Published: 2017

Journal Articles

Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma

Blood (2017) 130 (Supplement 1): 2742.

https://doi.org/10.1182/blood.V130.Suppl_1.2742.2742

Published: 2017

Journal Articles

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Blood (2017) 130 (Suppl_1): 736.

https://doi.org/10.1182/blood.V130.Suppl_1.736.736

Published: 2017

Journal Articles

The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study

Blood (2017) 130 (Supplement 1): 342.

https://doi.org/10.1182/blood.V130.Suppl_1.342.342

Published: 2017

NARROW

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

The Dramatic Impact of the War on Access to Treatment for Lymphoma Patients. a Report from the Ukrainian Lymphoma Registry

A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Adult T-Cell Leukemia/Lymphoma: A Cohort of 41 Cases Recorded in the Brazilian T-Cell Project

Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Outcome of Patients with Gamma Delta T Cell Lymphomas: Analysis of 1429 Cases Registered in the Prospective T-Cell Project

Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma

PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only